Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

The Benefits of Genetic Testing for Patients with CDKL5 Deficiency Disorder and Other Rare Genetic Epilepsies

(BPT) - CDKL5 deficiency disorder, one of the most common genetic epilepsies, is estimated to occur in approximately 100 newborns in the U.S. per year.

CDKL5 deficiency disorder, or CDD, is a rare, X-linked developmental and epileptic encephalopathy characterized by refractory seizures and severe global developmental impairment. The frequency of seizures related to CDD can vary, with some patients experiencing up to 20 seizures a day.

Those diagnosed with CDD face many challenges living with a rare disease and can experience a wide range of chronically debilitating symptoms, including early-onset seizures, global developmental impairment, and intellectual disability, as well as disorders related to sleep, speech, physical development, and cortical vision.

Although there is currently no cure for CDD, research into better understanding the disease and the development of treatment options continues to advance. In fact, in 2022 the FDA approved the first treatment specifically for seizures associated with CDD in appropriate patients.

As CDD is caused by a mutation in the CDKL5 gene, genetic testing is required for a diagnosis. With 70-80% of unexplained epilepsy cases now estimated to have a genetic cause, the use of improved genetic testing technologies has assisted in identifying the genes associated with epilepsy in patients and expanding diagnostic utility.

For patients with unexplained epilepsy, genetic testing results may influence their treatment plan, diet, and options to participate in suitable clinical trials for gene-specific studies that further enhance research in the space.

Furthermore, genetic testing is not restricted to pediatric patients. The National Society of Genetic Counselors (NSGC) recommends that all patients with unexplained epilepsy be offered genetic testing regardless of age and periodic reanalysis of prior test results, if needed.

'Finding the best care and resources for the CDD community is crucial to supporting the mental and physical wellbeing of patients and their families,' said John Flatt, M.D., Pediatric Neurologist and Medical Director at Marinus Pharmaceuticals. 'I encourage those affected by refractory seizures to discuss the resources available to them with their healthcare team, including genetic testing, treatment options, and counseling, to better understand their or their loved one's condition and explore tailored approaches to managing their symptoms.'

Confirming a diagnosis of a rare genetic epilepsy disorder such as CDD through genetic testing can help clinicians and families personalize treatment plans and best prepare for the challenges and treatment pathways ahead.

To learn more about CDD, access educational resources from trusted advocacy organizations, and read patient stories, visit the Marinus website, here: https://marinuspharma.com/focus-areas/cdkl5-deficiency-disorder-cdd/.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.